NEAH POWER SYSTEMS (OTCBB: NPWS)
"Up 244.44% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/NPWS.php

NEAH Power Systems, Inc. (NPWS) is developing long-lasting, efficient and safe power solutions for the military and for portable electronic devices. NEAH uses a unique, patented, silicon-based design for its micro fuel cells that enable higher power densities, lower cost and compact form-factors. The company's micro fuel cell system can run in aerobic and anaerobic modes.

NPWS News:

June 25 - NEAH Successfully Tests Anaerobic Direct Methanol Fuel Cell Prototype

NEAH Power Systems, Inc. (OTCBB: NPWS), the Company developing fuel cells for the military and portable electronic devices, announced today it has successfully demonstrated a new type of low cost, high reliability and power, liquid electrolyte based direct methanol fuel cell that does not require air to operate. This is the first major innovation in fuel cell technology in over 20 years, where a repeatable, reliable non-PEM based system has been successfully introduced and demonstrated in sustained operation.

The prototype was self contained and sized to generate 8W of gross power, fuel cartridges were replaced multiple times and repeatable performance demonstrated. A video of the technology, markets that NEAH serves, and demonstration of the technology will be posted on YouTube, as well as on the company's website, www.neahpower.com, and NEAH has invited any interested parties to visit the company to see the system in operation.

"We are thankful to the Office of Naval Research for funding significant portions of this research. This technology is singular in that it can operate in places where air isn't available," Dr. Chris D'Couto, NEAH's President and Chief Executive Officer, noted. "This system can service many specialized markets, such as underwater and surface water manned and unmanned vehicles, as well as numerous aerospace applications, and will be the building block for fuel cell solutions for Hobie Cat and other key customers." NEAH fuel cells operate in both an aerobic and anaerobic manner. "Our micro fuel cells may eventually replace batteries for most uses," D'Couto said, "meaning that cost-efficient and 'green' technology is at hand to not only preserve the environment, but to provide nearly perpetual power to the military, manufacturers of almost any product that require an energy source, and to the millions of consumers who require energy on the go."

ALTERNATIVE FUEL TECHNOLOGIES INCORPORATED (OTC: AFTC)
"Up 57.78% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/AFTC.php

Alternative Fuel Technology Inc. is a research & development organization engaged in the design, development and prototype manufacturing of advanced fuel systems for use with a new alternative fuel -- dimethyl either (DME). AFTC has developed practical, low-cost fuel injection equipment for DME fueled vehicles and currently provides complete DME fuel systems for testing and research purposes in addition to retrofit systems that can be used with most diesel engines. The company's ultimate goal is series production of DME fuel systems for the global automotive market by 2011.

AFTC News:

June 23 - Alternative Fuel Technologies Inc. Announces Test With Ford

Alternative Fuel Technologies (OTC: AFTC) announces that after the signing of a contract in 2008 with Ford Motor Company to supply them with a DME fuel system for a single cylinder alternative fuels/emissions research project, the Company is on schedule to make delivery of the DME Fuel System in August of this year. AFTC is using a Ford Land Rover 4-cylinder diesel engine that will fire only on one cylinder. The Company is testing this system now and all tests currently are on track for shipping. If successful, Ford has stated that they will do a full engine and car demonstration.

AFTC CEO James C. McCandless states, "Being that Ford is one of the Big 3 Auto Makers that has not been so negatively affected by the slowing economy, we are proud to have them as a potential client and help them steer the boat to meet today's demands." Mr. McCandless also states, "AFTC has positioned ourselves to be the leader in the DME Fuel System market, and winning this contract would be a great boost for the Company."

ABOUT DME

DME is a new ultra-clean diesel fuel replacement that can be produced from abundant resources. These include natural gas, landfill methane, coal and biomass. At current oil prices, DME can be produced and distributed at less than 1/2 the cost of conventional fuel. When burned in a diesel engine, all soot emissions are eliminated and NOx emissions are lowered dramatically without the use of expensive exhaust aftertreatment devices.

CHINA ARCHITECTURAL ENGINEERING INCORPORATED (NASDAQ: CAEI)
"Up 77.34% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/CAEI.php

China Architectural Engineering, Inc., which began operations in 1992, has maintained a leading position in the global commercial construction industry by providing timely, high-quality, reliable, fully integrated and cost-effective service solutions to our clients utilizing specialized technical expertise in the design, engineering, fabrication and construction of structural exterior cladding systems. It specializes in high-end curtain wall systems (including glass, stone and metal curtain walls), roofing systems, steel construction systems, eco-energy saving building conservation systems and related products, for public works and commercial real estate projects. CAEI has worked with world-renowned architects and building engineers from China and other countries and has completed over one-hundred large, complex and unique projects throughout China, Hong Kong, Macau, Australia and Southeast Asia, including numerous award-winning landmark buildings in many of Asia’s major cities. CAE has also expanded beyond China into some of the growing construction markets in the world, such as Middle East, Central Asia and Eastern Europe.

CAEI News:

June 24 - China Architectural Engineering Announces New Contract to Build Resort Near Shanghai

China Architectural Engineering, Inc. (Nasdaq: CAEI), a leader in the design, engineering, fabrication and installation of high-end building envelope systems, today announced that it has entered into a new agreement with Shanghai Nine Dragon Co., Ltd. to undertake the major projects located in the Nine Dragon Resort, Zhejiang, including a seven star hotel, a marine park and luxurious villas. The total project value is expected to exceed $500 million. The projects are expected to commence in the second half of 2009 and be completed within three years.

The Latest Update on the Current Projects

CAE’s work on the Dubai Metro System is expected to be completed in the third quarter as well as the projects in US and Doha, which will be completed within this year. CAE expects the project completions to provide more resources to build the aforesaid new projects. Meanwhile, due to the global financial crisis and other various factors, the company cannot utilize sufficient resources to continue the Singapore project. Given the uncertain global economic outlook and the limited company resources, CAE has decided to give up the project and reallocate resources towards other projects.

China Architectural Engineering Chairman and CEO Ken Yi Luo commented, “Our latest project update shows the effects of an uncertain global economic outlook. The termination of our Singapore project is a disappointment, of course, but it is also noteworthy that we continue to gain new business in our core domestic market of China. Here, our track record and extensive network of contacts in the public and private sectors are enabling us to take advantage of the Chinese government’s aggressive stimulus spending. In the future, we will gradually develop some good business that will produce steady revenues for the company to offset the impacts from the volatile construction industry.”

JAZZ PHARMACEUTICALS INCORPORATED (NASDAQ: JAZZ)
"Up 37.85% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/JAZZ.php

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry.

JAZZ News:

June 24 - Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

Preliminary top-line results of second Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled trial of sodium oxybate to treat fibromyalgia achieved its key endpoints. As in the first randomized, double-blind fibromyalgia study, sodium oxybate significantly decreased pain and fatigue and improved daily function and patient global impression of change. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.

"Fibromyalgia is a chronic illness, characterized by widespread pain, unrefreshing sleep, chronic fatigue, and psychological distress," said I. Jon Russell, M.D., Ph.D., lead investigator in the first Phase III study and Associate Professor of Medicine, Division of Clinical Immunology and Rheumatology, and Director, University Clinical Research Center, University of Texas Health Science Center at San Antonio. "Sodium oxybate has shown a positive effect on a number of the symptoms of fibromyalgia, and thus could have a significant impact on patients' quality of life."

The second 14-week Phase III trial, conducted in the United States and seven European countries, included 573 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/night, sodium oxybate 6 g/night, or placebo. The primary outcome measure, viewed by both U.S. and E.U. regulatory authorities as a clinically meaningful endpoint, was the proportion of patients who achieved at least 30 percent reduction in pain from baseline to endpoint based on the Pain Visual Analog Scale (VAS). Data from the Fibromyalgia Impact Questionnaire (FIQ) are considered equally relevant as Pain VAS data in the E.U. FIQ data are considered supportive data by U.S. regulators.

In the top-line results, significantly more patients treated with sodium oxybate achieved 30 percent or greater improvement in their pain compared to patients treated with placebo. Of those patients receiving sodium oxybate treatment, 35 percent of patients on 4.5 g/night and 35 percent of patients on 6 g/night reported this level of pain relief on the Pain VAS, compared with 20 percent of patients on placebo. These results were highly statistically significant.

Patients' physical functioning and ability to perform daily tasks, as measured by the FIQ, were highly statistically significantly different from placebo for the 4.5 g/night dose and for the 6 g/night dose. Sodium oxybate-treated patients also reported highly statistically significant improvement in fatigue, another common symptom of fibromyalgia.

The most common adverse events (greater than or equal to five percent and at least twice the rate of placebo) were nausea, dizziness, vomiting, insomnia, anxiety, somnolence, fatigue, muscle spasms, and peripheral oedema. Sodium oxybate was generally well tolerated, with the majority of adverse events reported being mild to moderate in nature.

"These results from our second Phase III trial, confirming the positive results of our first Phase III study, are an exciting milestone for Jazz Pharmaceuticals," said Bruce Cozadd, Chairman and Chief Executive Officer of Jazz Pharmaceuticals. "I'd like to thank the investigators, patients, and Jazz Pharmaceuticals employees who helped us complete this trial."

"UCB is committed to improving the lives of people living with severe CNS diseases," said Iris Loew-Friedrich, Chief Medical Officer of UCB. "The positive results of the two Phase III trials are encouraging and suggest that subject to regulatory approval, this may offer a new treatment option for people with fibromyalgia."

Only preliminary top-line efficacy and safety data are available at this time. Further analyses are planned, including analyses of additional secondary endpoints. Jazz Pharmaceuticals anticipates submitting a New Drug Application for sodium oxybate to the U.S. Food and Drug Administration (FDA) by the end of 2009. UCB will consult with the European Medicines Agency (EMEA) to define the path forward. UCB has the exclusive marketing and distribution rights to sodium oxybate for fibromyalgia in Europe and some other countries outside North America and will manage registrations accordingly.

CHDT CORPORATION (OTCBB: CHDO)
"Up 40.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/CHDO.php

CHDT Corp. is a public holding company that engages, through its wholly owned subsidiaries, in the development, manufacturing, logistics, and distribution of consumer products to retailers and wholesalers throughout North America.

CHDO News:

June 25 - Capstone Booklights Available at Costco Wholesale

South Florida based Capstone Industries, a wholly owned subsidiary of CHDT Corp. (OTCBB: CHDO), announced that it's all new Capstone Lighting 4 LED Book lights 2Pack is just now starting to become available at 403 Costco Wholesale locations for their back-to-school program.

The product consists of a dual pack of the new 4 LED book light that includes alkaline batteries and handy pouches. These convenient book lights feature a 3-position switch and a swivel light head with folding arm. Both compact and stylish, the book lights can be clipped to books or used free standing on ones night table.

For over 12 years, Capstone has been one of the recognized leaders in innovative and unique book lights, all purpose multi-task lights and novelty lights. Products are designed for the new "mobile" consumer-always on the go. Retailers nationwide acknowledge the creative packaging, practical and functional product features and value driven price points. Distribution comprises numerous and varied channels including mass market, drug and grocery, book chains, office supply, convenience stores, and automotive chains and warehouse clubs.

Focusing on the needs of the consumer, Capstone will continue to take a leadership position and produce thoughtfully designed products encompassing the latest lighting technologies, features and benefits.

UNIVERSAL PROPERTY DEVELOPMENT AND
ACQUISITION CORPORATION (OTCBB: UPDV)
"Up 33.33% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/UPDV.php

Universal Property Development and Acquisition Corporation (UPDA), through its subsidiaries, engages in the acquisition, exploration, production, development, storage, and distribution of oil and natural gas in Texas and Kansas. The company also involves in the purchase, transportation, storage, and resale of petroleum products. In addition, it provides drilling, pipeline construction, and well maintenance and development services. The company, formerly known as Procore, Inc., was incorporated in 1982 and is based in Juno Beach, Florida.

UPDV News:

June 15 - UPDA Completes New Line of Credit Financing with Ashford Financial; Positioned to Compete to Purchase Crude Oil from Major Producers; Management also Negotiating New Purchase Contract to Expand Margins

Universal Property Development and Acquisition Corporation (OTC: UPDV) has completed the previously announced line of credit financing with Ashford Financial of New York. This new financing will provide UPDA with access to $5.25 million which will establish a competitive advantage as it negotiates new purchase agreements with major crude oil producers.

“We can now make immediate payment for the oil we purchase,” indicated UPDA CEO Tim Brink. “This will give us a significant competitive advantage since most of our competitors pay only once a month an average of 45 days after pick-up while we will be in a position to pay our producers immediately each time we pick up their oil. Certainly we expect that most of the major producers will prefer these payment terms which should allow us to greatly expand our market area.”

UPDA is also near completion of negotiations on a long term contract to sell the crude oil it purchases and transports. These negotiations, also with a major oil company, will establish larger margins and further improve UPDA’s competitiveness.

“Once we sign the new sales agreement for the oil we purchase and transport, our sales margins will be greatly expanded, predictable and consistent,” continued CEO Brink. “With the spot contracts we had previously been operating under, our margins changed from day to day and we were unable to offer our customers any consistency in the prices we were paying. With this new contract, we can offer our customers certainty in the price they will be paid and with the new financing, we can make immediate payment for the product. We will now be able to compete to provide oil transport services to every player in the market and we will be making bigger profits on every barrel of oil we move. We will not only have much bigger revenues, we will also have much better margins. These are significant developments as we move forward.”